再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REGN 再生元制药公司

交易中 07-22 14:51:17 EDT

1,071.32

+7.72

+0.73%

最高1,078.71	最低1,064.95	成交量12.10万
今开1,075.35	昨收1,063.60	日振幅1.29%
总市值1,156亿	流通市值1,108亿	总股本1.08亿
成交额1.29亿	换手率0.12%	流通股本1.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":1071.32,"timestamp":1721674268993,"preClose":1063.6,"halted":0,"volume":120965,"delay":0,"floatShares":103389234,"shares":107885503,"eps":33.84642,"marketStatus":"交易中","marketStatusCode":2,"change":7.72,"latestTime":"07-22 14:51:17 EDT","open":1075.35,"high":1078.705,"low":1064.95,"amount":129498717.855,"amplitude":0.012932,"askPrice":1071.86,"askSize":29,"bidPrice":1071.24,"bidSize":105,"shortable":3,"etf":0,"ttmEps":33.84642,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1721678400000},"adr":0,"adjPreClose":1063.6,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":1069.52,"preClose":1063.6,"latestTime":"09:13 EDT","volume":7518,"amount":7997184.5394,"timestamp":1721654017123},"postHourTrading":{"tag":"盘后","latestPrice":1063.6,"preClose":1063.6,"latestTime":"19:53 EDT","volume":31977,"amount":34011558.3924,"timestamp":1721433228382},"volumeRatio":0.360874,"impliedVol":0.2889,"impliedVolPercentile":0.8207},"requestUrl":"/m/hq/s/REGN/tweets","defaultTab":"tweets","newsList":[{"id":"2451915996","title":"再生元制药公司涨1.65% 股价突破1100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2451915996","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451915996?lang=zh_cn&edition=full","pubTime":"2024-07-16 22:05","pubTimestamp":1721138709,"startTime":"0","endTime":"0","summary":"北京时间2024年07月16日22时05分，再生元制药公司股票出现异动，股价急速拉升1.65%。截至发稿，该股报1100.00美元/股，成交量1.979万股，换手率0.02%，振幅1.89%。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.87%。其相关个股中，Silo Pharma, Inc.、Conduit Pharmaceuticals Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Silo Pharma, Inc.、Scisparc Ltd.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为1802.65%、1038.62%、96.50%，振幅较大的相关个股有Scisparc Ltd.、Silo Pharma, Inc.、Conduit Pharmaceuticals Inc.，振幅分别为40.48%、40.19%、39.04%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240716220509941f773f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240716220509941f773f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2362540622.SGD","LU0889565916.HKD","LU0882574055.USD","BK4585","LU1917777945.USD","REGN","LU2362541513.USD","LU1974910355.USD","LU2106854487.HKD","BK4588","LU0109394709.USD","LU0114720955.EUR","LU0053666078.USD","LU0823416689.USD","LU0320765992.SGD","LU0289739699.SGD","LU2023250504.SGD","LU0058720904.USD","LU2362541273.HKD","BK4139"],"gpt_icon":0},{"id":"2451628422","title":"再生元制药公司跌0.82% 股价跌破1100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2451628422","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451628422?lang=zh_cn&edition=full","pubTime":"2024-07-15 21:32","pubTimestamp":1721050328,"startTime":"0","endTime":"0","summary":"北京时间2024年07月15日21时32分，再生元制药公司股票出现波动，股价大幅跳水0.82%。截至发稿，该股报1090.98美元/股，成交量9660股，换手率0.01%，振幅0.62%。最近的财报数据显示，该股实现营业收入31.45亿美元，净利润7.22亿美元，每股收益6.70美元，毛利25.97亿美元，市盈率32.21倍。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.18%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407152132089f4f2315&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407152132089f4f2315&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0823416689.USD","REGN","BK4139","LU2362541273.HKD","LU0109394709.USD","LU2106854487.HKD","BK4588","LU0289739699.SGD","LU2023250504.SGD","LU2362540622.SGD","LU0320765992.SGD","LU1974910355.USD","LU0882574055.USD","LU1917777945.USD","LU0053666078.USD","LU0058720904.USD","LU0114720955.EUR","LU0889565916.HKD","BK4585","LU2362541513.USD"],"gpt_icon":0},{"id":"2450537289","title":"再生元制药公司涨2.07% 股价突破1100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2450537289","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450537289?lang=zh_cn&edition=full","pubTime":"2024-07-12 23:32","pubTimestamp":1720798341,"startTime":"0","endTime":"0","summary":"北京时间2024年07月12日23时32分，再生元制药公司股票出现波动，股价快速上涨2.07%。截至发稿，该股报1102.65美元/股，成交量9.6348万股，换手率0.09%，振幅1.37%。再生元制药公司股票所在的生物技术行业中，整体涨幅为1.57%。再生元制药公司公司简介：Regeneron制药公司发现、开发并商业化对抗眼疾、心血管疾病、癌症和炎症的产品。消息层面，截至23时32分，《摩根士丹利维持再生元制药公司买入评级，下调目标价至1,182美元》资讯为影响再生元制药公司的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712233222af922082&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712233222af922082&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2106854487.HKD","LU2362540622.SGD","BK4588","BK4585","LU1917777945.USD","LU1974910355.USD","LU0882574055.USD","LU2023250504.SGD","LU2362541273.HKD","LU0058720904.USD","LU0289739699.SGD","LU0823416689.USD","REGN","LU0320765992.SGD","LU0109394709.USD","LU2362541513.USD","LU0889565916.HKD","BK4139","LU0114720955.EUR","LU0053666078.USD"],"gpt_icon":0},{"id":"2448145428","title":"再生元(REGN.US)/赛诺菲(SNY.US)Dupixent在欧盟获批用于治疗慢性阻塞性肺病成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2448145428","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448145428?lang=zh_cn&edition=full","pubTime":"2024-07-04 08:00","pubTimestamp":1720051242,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月3日，欧洲药品管理局批准了再生元与赛诺菲的重磅疗法Dupixent作为一种附加维持治疗药物，用于治疗以血液嗜酸性粒细胞升高为特征、且未得到控制的慢性阻塞性肺病成人患者。根据新闻稿，Dupixent是欧盟地区十多年来被批准用于治疗COPD的首款新疗法，这也是Dupixent首次获全球监管单位批准用于治疗COPD。目前，该疗法正在包括美国、中国和日本在内的全球监管机构接受审查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0289739699.SGD","LU2106854487.HKD","BK4007","LU1974910355.USD","BK4585","BK4588","LU0053666078.USD","LU0058720904.USD","SNY","LU2023250504.SGD","LU0114720955.EUR","REGN","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","LU1917777945.USD","LU0882574055.USD","LU2362540622.SGD","LU2362541273.HKD","LU2362541513.USD"],"gpt_icon":0},{"id":"2443636152","title":"BUZZ-Replimune 获得 1 亿美元 PIPE 融资后反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2443636152","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443636152?lang=zh_cn&edition=full","pubTime":"2024-06-14 00:53","pubTimestamp":1718297614,"startTime":"0","endTime":"0","summary":"    6月13日 - ** 生物技术公司Replimune Group   周四私募融资1亿美元，股价上涨8.3%，报9.55美元。** 公司表示将利用所得资金 \"全面扩大 \"RP1 在皮肤癌领域的商业化，并用于营运资金和一般用途。** 12月5日，RP1与Regeneron公司  的抗体药物Libtayo联用在中期研究中失败后，REPL暴跌  45%至6.75美元。** Replimune 拥有约 6 140 万股已发行股票和约 5 680 万股公众流通股 - LSEG** 该公司于 2018 年以 15 美元的价格首次公开募股，其股价最高曾达到 54.85 美元** 利瑞克担任 PIPE 的独家配售代理","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU0058720904.USD","REGN","LU0889565916.HKD","LU2362540622.SGD","REPL","BK4588","LU1974910355.USD","LU2023250504.SGD","LU0053666078.USD","LU0114720955.EUR","LU2362541513.USD","LU2362541273.HKD","LU0882574055.USD","LU0109394709.USD","LU1917777945.USD","BK4139","BK4585","BUZZ","LU0289739699.SGD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2442394869","title":"再生元制药公司跌0.10% 股价跌破1000美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2442394869","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442394869?lang=zh_cn&edition=full","pubTime":"2024-06-11 21:31","pubTimestamp":1718112662,"startTime":"0","endTime":"0","summary":"北京时间2024年06月11日21时31分，再生元制药公司股票出现异动，股价大幅下挫0.10%。截至发稿，该股报1000.69美元/股，成交量3613股，换手率0.00%，振幅0.26%。再生元制药公司股票所在的生物技术行业中，整体跌幅为0.45%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、180 Life Sciences Corp C/Wts 07/11/2025、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大，Clearmind Medicine Inc.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为128.68%、51.76%、26.27%，振幅较大的相关个股有康乃德生物、Trevi Therapeutics, Inc.、Unicycive Therapeutics, Inc.，振幅分别为10.76%、9.88%、8.08%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061121310295a4f3ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061121310295a4f3ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2106854487.HKD","LU0058720904.USD","LU0882574055.USD","LU2023250504.SGD","LU2362540622.SGD","BK4585","LU0889565916.HKD","LU2362541513.USD","BK4588","LU0289739699.SGD","LU0320765992.SGD","LU0053666078.USD","LU0114720955.EUR","BK4139","LU0109394709.USD","REGN","LU1974910355.USD","LU2362541273.HKD","LU1917777945.USD"],"gpt_icon":0},{"id":"2441728123","title":"再生元制药公司跌0.59% 股价跌破1000美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2441728123","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441728123?lang=zh_cn&edition=full","pubTime":"2024-06-07 01:46","pubTimestamp":1717696002,"startTime":"0","endTime":"0","summary":"北京时间2024年06月07日01时46分，再生元制药公司股票出现异动，股价大幅下挫0.59%。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.84%。消息层面，截至01时46分，《Form 144 | 再生元制药公司董事拟出售827股股份，价值约83.61万美元》资讯为影响再生元制药公司的重要信息。关联方在任何三个月期间出售的股票数量超过5,000股时，或总市值超5万美元时须向SEC提交该表格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024060701464396812a78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024060701464396812a78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1917777945.USD","LU2106854487.HKD","BK4588","LU0320765992.SGD","BK4139","LU0882574055.USD","LU0889565916.HKD","LU2023250504.SGD","LU1974910355.USD","LU0109394709.USD","LU0053666078.USD","LU0289739699.SGD","LU2362540622.SGD","LU0114720955.EUR","LU2362541513.USD","REGN","LU0058720904.USD","BK4585","LU2362541273.HKD"],"gpt_icon":0},{"id":"2440366042","title":"再生元制药公司涨1.06% 股价突破1000美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2440366042","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440366042?lang=zh_cn&edition=full","pubTime":"2024-06-04 22:00","pubTimestamp":1717509636,"startTime":"0","endTime":"0","summary":"北京时间2024年06月04日22时00分，再生元制药公司股票出现异动，股价急速上涨1.06%。截至发稿，该股报1000.00美元/股，成交量2.0812万股，换手率0.02%，振幅1.23%。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.29%。其相关个股中，Annexon, Inc.、Cingulate Inc C/Wts 10/12/2026 、Seastar Medical Holding Corp C/Wts 28/10/2027 涨幅较大，Bio-Path Holdings, Inc.、Fresh2 Group Limited、Annexon, Inc.较为活跃，换手率分别为50.26%、37.72%、29.58%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 29/04/2026 、Annexon, Inc.、Silo Pharma, Inc.，振幅分别为181.00%、31.22%、28.08%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604220037941ec458&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604220037941ec458&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2106854487.HKD","LU0058720904.USD","REGN","LU0889565916.HKD","LU2362540622.SGD","BK4588","LU1974910355.USD","LU2023250504.SGD","LU0053666078.USD","LU0114720955.EUR","LU2362541513.USD","LU2362541273.HKD","LU0882574055.USD","LU0109394709.USD","LU1917777945.USD","BK4139","BK4585","LU0289739699.SGD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2439699084","title":"美国FDA推迟审批再生元(REGN.US)/赛诺菲(SNY.US)Dupixent用于治疗COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2439699084","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439699084?lang=zh_cn&edition=full","pubTime":"2024-05-31 21:49","pubTimestamp":1717163348,"startTime":"0","endTime":"0","summary":"再生元制药公司(REGN.US)和赛诺菲(SNY.US)周五宣布，美国FDA推迟对其重磅药物Dupixent (dupilumab)用于治疗慢性阻塞性肺疾病(COPD)的决定。","market":"us","thumbnail":"https://img.zhitongcaijing.com/source/image/46130.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/source/image/46130.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1129509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2023250504.SGD","REGN","LU1917777945.USD","BK4588","LU2362540622.SGD","LU2362541273.HKD","LU0289739699.SGD","SNY","LU0053666078.USD","LU0889565916.HKD","BK4139","LU2362541513.USD","LU2106854487.HKD","LU0882574055.USD","LU0114720955.EUR","LU0320765992.SGD","LU0109394709.USD","BK4585","LU1974910355.USD","BK4007","LU0058720904.USD"],"gpt_icon":0},{"id":"2439934927","title":"美国食品药品管理局延长赛诺菲公司用于治疗 \"吸烟者肺病 \"的Dupixent的最后期限并要求提供更多数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2439934927","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439934927?lang=zh_cn&edition=full","pubTime":"2024-05-31 13:28","pubTimestamp":1717133298,"startTime":"0","endTime":"0","summary":"赛诺菲去年 ，在第二次大型试验显示其抗炎药物Dupixent对慢性阻塞性肺病有显著疗效后，赛诺菲表示将寻求美国批准其Dupixent用于慢性阻塞性肺病的治疗，以拓宽其大片药物的市场。赛诺菲在另一份新闻稿中说，欧盟药品管理局CHMP对在欧洲批准Dupixent作为嗜酸性粒细胞升高的慢性阻塞性肺病的附加维持治疗给予了积极的建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1974910355.USD","LU0889565916.HKD","LU0114720955.EUR","REGN","LU2023250504.SGD","LU0053666078.USD","LU2106854487.HKD","LU0320765992.SGD","BK4585","LU0058720904.USD","LU0882574055.USD","LU1917777945.USD","LU0289739699.SGD","BK4588","LU0109394709.USD"],"gpt_icon":0},{"id":"2437461766","title":"美国研究综述-Chemed、PTC Therapeutics、Regeneron Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2437461766","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437461766?lang=zh_cn&edition=full","pubTime":"2024-05-21 14:45","pubTimestamp":1716273908,"startTime":"0","endTime":"0","summary":"    路透5月21日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Chemed、PTC Therapeutics 和 Regeneron Pharmaceuticals。* Regeneron Pharmaceuticals Inc   ：杰富瑞将预测价格从1125美元上调至1135美元              * United Therapeutics Corp   ：摩根大通将目标价从280美元上调至300美元  以下是路透周二报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LENZ","ALTG","BK4146","LU0211326839.USD","BK4576","IE00B3S45H60.SGD","IE00BLSP4239.USD","BK4104","BOOT","DECK","APA","LU0256863811.USD","NCLH","BK4550","BK4167","IE00BMPRXR70.SGD","FLO","IE00BBT3K403.USD","INSG","LU0058720904.USD","OC","CHE","IE00BWXC8680.SGD","LU2286300806.USD","SJM","TDOC","REGN","LU1169589451.USD","LU1244550577.SGD","LU0320765992.SGD","BK4142","IE00B1XK9C88.USD","IE00B1BXHZ80.USD","BK4548","IE00B19Z9505.USD","LU0868494617.USD","PTC","DOMO","DXC","LU0211327993.USD","BK4139","DK","PANW","SPIR","UTHR","BK4532","PTCT","BK4086","ULS"],"gpt_icon":0},{"id":"2436010281","title":"更新版 1-美国 FDA 批准两款生物仿制药替代大片眼药 Eylea","url":"https://stock-news.laohu8.com/highlight/detail?id=2436010281","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436010281?lang=zh_cn&edition=full","pubTime":"2024-05-20 23:00","pubTimestamp":1716217245,"startTime":"0","endTime":"0","summary":"     路透5月20日 - 美国食品和药物管理局周一批准了Regeneron Pharmaceuticals公司  的大片眼药Eylea的两个近似复制品 ，这可能会损害该公司将更高剂量版本的治疗药物推向市场的努力。根据美国食品及药物管理局  网站上的信息，该局 批准了Biocon Biologics公司的生物仿制药Yesafli以及三星生物公司和百健公司   的Opuviz 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU1974910355.USD","LU0882574055.USD","BK4585","BK4588","IE00B894F039.SGD","LU0109394709.USD","IE00B19Z9P08.USD","REGN","LU0114720955.EUR","LU0889565916.HKD","BK4533","BK4139","LU0058720904.USD","IE00B19Z9Z06.USD","BK4532","LU0320765992.SGD","LU0289739699.SGD","BIIB","LU1917777945.USD","LU2023250504.SGD","LU0053666078.USD","LU2106854487.HKD"],"gpt_icon":1},{"id":"2436090581","title":"美国食品和药物管理局批准 Biocon 公司的生物仿制药替代大片眼药 Eylea","url":"https://stock-news.laohu8.com/highlight/detail?id=2436090581","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436090581?lang=zh_cn&edition=full","pubTime":"2024-05-20 22:31","pubTimestamp":1716215494,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透5月20日 - 美国食品和药物管理局网站的信息显示，该局周一批准了百康  部门生产的 Regeneron Pharmaceuticals  大片眼药Eylea的生物仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0882574055.USD","LU0289739699.SGD","REGN","BK4139","LU0889565916.HKD","BK4585","LU0053666078.USD","LU0109394709.USD","LU0320765992.SGD","LU1917777945.USD","BK4588","LU0114720955.EUR","LU2023250504.SGD","LU2106854487.HKD","LU1974910355.USD"],"gpt_icon":0},{"id":"2436612841","title":"美国研究综述-阿里斯塔网络公司、新月能源公司、戴尔科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2436612841","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436612841?lang=zh_cn&edition=full","pubTime":"2024-05-20 14:56","pubTimestamp":1716188173,"startTime":"0","endTime":"0","summary":"    路透5月20日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 Arista Networks、Crescent Energy 和戴尔科技。* 戴尔科技公司  ：摩根大通将目标价从125美元上调至155美元              * Loar Holdings Inc   ：加拿大皇家银行给予 \"跑赢大盘 \"评级；目标价60美元              * Regeneron Pharmaceuticals Inc   ：Jefferies将其目标价从1,060美元上调至1,115美元。* 安特罗资源公司  ：Gerdes Energy Research将其评级从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LITE","FTRE","BK4551","AR","BK4559","IE00BMPRXR70.SGD","IIPR","BK4170","LU1917777945.USD","LU2106854487.HKD","SNOW","BK4588","LOAR","BK4177","BK4139","PRMW","EWTX","LU0109392836.USD","BK4581","DAR","BHVN","LU2023250504.SGD","BK4020","LU1974910355.USD","KGS","BK4212","BK4503","LU0109394709.USD","BK4121","BK4007","BK4182","LU0289739699.SGD","BK4505","LU0289739343.SGD","FLO","NMRA","IE00BMPRXN33.USD","ANET","HCAT","CRGY","LU1803068979.SGD","AZZ","LU0114720955.EUR","BK4213","LU0289961442.SGD","REGN","BK4515","DELL","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2436112733","title":"高中生科学家和工程师在 2024 年 Regeneron 国际科学与工程大奖赛中获得逾 900 万美元奖金","url":"https://stock-news.laohu8.com/highlight/detail?id=2436112733","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436112733?lang=zh_cn&edition=full","pubTime":"2024-05-20 09:53","pubTimestamp":1716169980,"startTime":"0","endTime":"0","summary":"恭喜 Krish Pai、Grace Sun 和 Michelle Wei，他们在加利福尼亚州洛杉矶举行的 2024 年 Regeneron 国际科学与工程博览会上名列前茅  夺冠选手分别在两次颁奖典礼获得表彰：5 月 16 日的特别奖和 5 月 17 日上午的盛大颁奖典礼。科学学会主席兼首席执行官、《科学新闻》执行出版商 Maya Ajmera 表示：\"恭喜 2024 年 Regeneron 国际科学与工程大奖赛的获胜者。自 2020 年以来，Regeneron 已为约 240 万名学生提供了 STEM 体验，并且有望实现到 2025 年达到 250 万学生的目标。其项目将代表 Regeneron ISEF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4417917_ZH17917_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2023250504.SGD","REGN","LU1917777945.USD","BK4096","BK4588","LU0289739699.SGD","LU0053666078.USD","LU0889565916.HKD","STEM","BK4139","LU1169589451.USD","LU2106854487.HKD","LU0882574055.USD","LU1169590202.USD","LU0114720955.EUR","LU0320765992.SGD","BK4535","LU0109394709.USD","BK4585","LU1974910355.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2436994744","title":"BUZZ-券商等待安进公司的肺病药物数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2436994744","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436994744?lang=zh_cn&edition=full","pubTime":"2024-05-17 18:35","pubTimestamp":1715942133,"startTime":"0","endTime":"0","summary":"    5月17日 - ** 券商等待安进  和再生元  在周日公布试验数据，这两家公司都在争夺其慢性阻塞性肺病试验性治疗药物的市场份额** BMO Capital Markets认为，投资者将重点关注AMGN的药物Tezspire与REGN的Dupixent在嗜酸性粒细胞白细胞数量较高的慢性阻塞性肺病患者中的疗效对比。** 预计美国 FDA 将在 6 月 27 日前就 Dupixent 用于治疗慢性阻塞性肺病做出决定** 慢性阻塞性肺病是一种常见的肺部疾病，会导致气流受限和呼吸困难** 截至收盘，AMGN股价上涨9.3%，REGN上涨10.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","BK4533","IE00BJT1NW94.SGD","LU2242652126.USD","BK4581","LU0109394709.USD","LU0114720955.EUR","LU1057294990.SGD","SG9999001440.SGD","LU2106854487.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4566","LU0053666078.USD","LU2023250504.SGD","AMGN","LU1571399168.USD","LU0889565916.HKD","IE00B2B36J28.USD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1917777945.USD","BK4585","LU0058720904.USD","LU1974910355.USD","IE0009355771.USD","BK4588","LU0289739699.SGD","BUZZ","IE0002141913.USD","LU2242646821.SGD","BK4534","BK4139","LU0868494617.USD","REGN","LU0122379950.USD"],"gpt_icon":0},{"id":"2434691658","title":"再生元制药公司2024财年第一财季实现净利润7.22亿美元，同比减少11.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434691658","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434691658?lang=zh_cn&edition=full","pubTime":"2024-05-11 00:16","pubTimestamp":1715357805,"startTime":"0","endTime":"0","summary":"3月31日，再生元制药公司公布财报，公告显示公司2024财年第一财季净利润为7.22亿美元，同比减少11.74%；其中营业收入为31.45亿美元，同比减少0.54%，每股基本收益为6.70美元。从资产负债表来看，再生元制药公司总负债73.79亿美元，其中短期债务0.00美元，资产负债比为4.66，流动比率为5.28。机构评级：截至2024年3月31日，当前有23家机构对再生元制药公司目标价做出预测，其中目标均价为1053.18美元，其中最低目标价为720.00美元，最高目标价为1185.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051100165487516c75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051100165487516c75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REGN"],"gpt_icon":0},{"id":"2433745230","title":"Regeneron 的实验性基因疗法改善了一名患者的听力","url":"https://stock-news.laohu8.com/highlight/detail?id=2433745230","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433745230?lang=zh_cn&edition=full","pubTime":"2024-05-08 18:08","pubTimestamp":1715162900,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透5月8日 - Regeneron Pharmaceuticals   公司周三表示，在一项早期和中期研究中，该公司正在研究的基因疗法可在24周内将一名儿童的听力提高到正常水平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0053666078.USD","LU1974910355.USD","BK4139","LU2106854487.HKD","LU2023250504.SGD","LU0114720955.EUR","BK4588","LU0889565916.HKD","LU0320765992.SGD","BK4585","LU0882574055.USD","LU1917777945.USD","LU0058720904.USD","REGN","LU0289739699.SGD"],"gpt_icon":0},{"id":"2432902291","title":"坎托菲茨杰拉德公司：重申Regeneron Pharmaceuticals(REGN.US)评级，由中性调整至中性评级, 目标价925.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432902291","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432902291?lang=zh_cn&edition=full","pubTime":"2024-05-03 23:35","pubTimestamp":1714750511,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申Regeneron Pharmaceuticals(REGN.US)评级，由中性调整至中性评级, 目标价925.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050323351287ceca9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050323351287ceca9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REGN"],"gpt_icon":0},{"id":"2432609911","title":"再生元制药公司公布截至一月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2432609911","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432609911?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:32","pubTimestamp":1714656721,"startTime":"0","endTime":"0","summary":"   * Regeneron Pharmaceuticals Inc    公布的截至 1 月份的季度调整后每股收益为 9.55 美元，低于去年同期的每股收益 10.09 美元。华尔街预期为每股收益 8.56 美元至 11.62 美元。* Regeneron Pharmaceuticals Inc公布的本季度每股收益为6.27美元。* 公司报告的季度净收入为 7.22 亿美元。* Regeneron Pharmaceuticals Inc 本季度股价下跌了 6.1%，今年迄今为止上涨了 2.9%。* 华尔街对 Regeneron Pharmaceuticals Inc 的 12 个月目标价中位数为 1,060.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0114720955.EUR","LU0882574055.USD","LU1974910355.USD","LU2023250504.SGD","LU0109394709.USD","LU0320765992.SGD","LU1917777945.USD","LU0058720904.USD","REGN","LU0889565916.HKD","LU2106854487.HKD","BK4585","BK4588","LU0053666078.USD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0331},{"period":"1month","weight":0.0236},{"period":"3month","weight":0.186},{"period":"6month","weight":0.1395},{"period":"1year","weight":0.4711},{"period":"ytd","weight":0.211}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.041845},{"month":2,"riseRate":0.393939,"avgChangeRate":0.089316},{"month":3,"riseRate":0.484848,"avgChangeRate":-0.042863},{"month":4,"riseRate":0.484848,"avgChangeRate":0.019407},{"month":5,"riseRate":0.647059,"avgChangeRate":0.064499},{"month":6,"riseRate":0.411765,"avgChangeRate":0.00486},{"month":7,"riseRate":0.647059,"avgChangeRate":0.052611},{"month":8,"riseRate":0.515152,"avgChangeRate":0.019343},{"month":9,"riseRate":0.484848,"avgChangeRate":0.029068},{"month":10,"riseRate":0.393939,"avgChangeRate":-0.00018},{"month":11,"riseRate":0.545455,"avgChangeRate":0.046018},{"month":12,"riseRate":0.515152,"avgChangeRate":0.048311}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}